Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Acrivon Therapeutics to post earnings of ($0.66) per share for the quarter.
Acrivon Therapeutics Stock Performance
Shares of ACRV opened at $5.39 on Wednesday. The company has a market capitalization of $167.82 million, a PE ratio of -2.00 and a beta of 0.85. The company’s 50 day moving average price is $5.54 and its 200 day moving average price is $6.63. Acrivon Therapeutics has a 52 week low of $4.69 and a 52 week high of $11.90.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on ACRV shares. KeyCorp initiated coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Cantor Fitzgerald assumed coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.67.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Further Reading
- Five stocks we like better than Acrivon Therapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- 3 Grocery Stocks That Are Proving They Are Still Essential
- NVIDIA Insiders Sell: This Is What It Means for the Market
- How to Invest in Blue Chip Stocks
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
